Pholcodine Linctus B.P 200 ml

Therapeutic indications:

Pholcodine linctus for the symptomatic relief of unproductive coughs.

For oral administration.

Posology and method of administration: pholcodine linctus

Adults and children over 12 years: Two 5ml spoonfuls.

Elderly: The normal adult dose is still appropriate in the elderly.

Children 6 to 12 years: One 5ml spoonful.

The dose may be taken, if necessary, 3 to 4 times daily.

This medicine is contraindicated in children under 6 years of age (See section 4.3).

Children of 6-12 years of age: not to be used for more than 5 days without the advice of a doctor. Parents or carers should seek medical attention if the child’s condition deteriorates during treatment.

Do not exceed the stated dose.

Keep all medicines out of the sight and reach of children.

Contraindications pholcodine linctus

Hypersensitivity to the active substance or any of the excipients.

Pholcodine should not be given to subjects in, or at risk of developing respiratory failure (may depress respiration).

Patients with chronic bronchitis, COPD, bronchiolitis or bronchiectasis due to sputum retention.

Patients with renal or hepatic failure.

Patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping such treatment (see also section 4.5).

Not to be used in children under the age of 6 years.

Special warnings and precautions for use

Should be used with caution by patients with liver or renal disease.

Ask a doctor before use if you suffer from a chronic or persistent cough, if you have asthma or are suffering from an acute asthma attack or where cough is accompanied by excessive secretions.

Do not take with any other cough and cold medicine.

Use of pholcodine with alcohol or other CNS depressants may increase the effects on the CNS and cause toxicity in relatively smaller doses.

If symptoms persist consult your doctor.

Interaction with other medicinal products and other forms of interaction

Not to be used in patients taking MAOIs or within 14 days of stopping treatment. Interaction with neuromuscular blocking agents (anaphylaxis) has been reported.